ThirtyFiveBio is developing a novel small molecule therapeutic that acts as a gut epithelial shield for ulcerative colitis. By inhibiting GPR35, their therapy corrects epithelial dysfunction and protects the gut lining from inflammatory factors, aiming to improve treatment response for UC patients.
Funding
$27.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current anti-inflammatory treatments for ulcerative colitis (UC) demonstrate limited efficacy, with a significant proportion of patients being non-responders or experiencing relapses. This necessitates novel therapeutic approaches that address the underlying disease causality to improve both immediate and long-term patient outcomes.
Solution
ThirtyFiveBio is developing a novel therapeutic agent designed to act as a gut epithelial shield, specifically targeting the inflammatory cascade in ulcerative colitis. The core of this approach involves GPR35 inhibition, a mechanism aimed at correcting epithelial dysfunction and damage characteristic of the disease. By protecting the gut epithelium from inflammatory factors, this therapy seeks to elevate the response ceiling for UC treatment, offering a more robust and sustained resolution for patients. This strategy targets a fundamental aspect of UC pathology, potentially disrupting current treatment paradigms.
Target Audience
The primary target audience includes patients diagnosed with ulcerative colitis and healthcare providers specializing in gastroenterology and inflammatory bowel disease management.
Features
- Development of a GPR35 antagonist small molecule therapeutic.
- Mechanism of action focuses on correcting epithelial dysfunction and damage in the gut.
- Designed to protect the gut epithelium from inflammatory factors implicated in colitis.
- Proprietary lead molecule with multiple series under patent protection.
- Advanced synthetic route and scale-up process for lead antagonist.
- Preclinical research includes patient-derived colitis epithelium models.